Celebrex is the only COX-2 inhibitor still on the market in the United States. The popular painkiller has been used by millions of Americans and Pfizer is expecting over $2 Billion in sales from the drug Celebrex in 2007 alone.
Celebrex is however linked to serious adverse side effects including heart attacks, strokes and Stevens Johnson Syndrome (SJS).
Update: Schmidt & Clark is no longer accepting Celebrex cases.
The Food & Drug Administration in 2005 asked their advisory committee to examine the drug Celebrex to determine whether it offered enough benefits to the consumer stay on the market and whether or not they needed to add stronger warnings to the package inserts. The advisory committee indicated that Celebrex elevates the chances of cardiovascular problems.
Dr. Garret Fitzgerald, a researcher at the University of Pennsylvania, has told the US regulatory panel governing the drug Celebrex that all COX-2 inhibitors increase the risk of heart attacks and strokes. Dr. Fitzgerald has indicated that the body will react the same to Celebrex as it does to Vioxx or Bextra, which have both been removed from the market. Furthermore, Dr. Fitzgerald said that Celebrex creates an imbalance in the body's cardiovascular system that may lead to an increased risk of heart attacks and strokes.
| Secure your Vista PC in 10 simple steps - ITBusiness.ca In its fresh-from-the-box configuration, Vista still leaves a chance for your personal data to leak out to the Web through Windows Firewall or for some nefarious bot to tweak your browser settings without your knowledge. But by making a few judicious ... Code puts cap on drug companies - Houston Chronicle Pens and prescription pads emblazoned with name-brand drug logos are as commonplace as stethoscopes in many doctor's offices. That all changed Thursday. The Pharmaceutical Research and Manufacturers of America, the major lobbying group for drug ... |